Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease

Francesca Palone, Roberta Vitali, Salvatore Cucchiara, Maria Pierdomenico, Anna Negroni, Marina Aloi, Federica Nuti, Carla Felice, Alessandro Armuzzi, Laura Stronati

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Noninvasive biomarkers of high- and low-grade intestinal inflammation and of mucosal healing (MH) in patients with inflammatory bowel disease are currently lacking. We have recently shown that fecal high mobility group box 1 (HMGB1) protein is a novel biomarker of gut inflammation. We aimed at investigating in a mouse model if HMGB1 was able to foresee both a clinically evident and a subclinical gut inflammation and if its normalization indicated MH. We also aimed at confirming the results in patients with Crohn's disease (CD) and ulcerative colitis.
Original languageEnglish
Pages (from-to)1448-1457
Number of pages10
JournalInflammatory Bowel Diseases
Volume20
DOIs
Publication statusPublished - 2014

Keywords

  • biomarker
  • inflammatory bowel disease

Fingerprint

Dive into the research topics of 'Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal healing in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this